Novel Anti-Fibrotic Agent GB2064 in Myelofibrosis

[Manouche]

« We are looking at alternative options in terms of targeting fibrosis. The next wave of clinical studies that we can anticipate [will include] an expansion of our efforts to look at the biology of the disease to try to eliminate fibrosis or prevent fibrosis from developing. I would hope that in the near future we are going to be talking about prevention studies rather than intervention studies,”

onclive.com/view/mylox-1-tr...

[EmeraldA]

This would be brilliant!!

[MPort]

Great to know.

[Bluetop]

Prevention would be great!

[Aneliv9]

Optimistic but prevention studies take at least 10 years i think??

[Manouche in reply to Aneliv9]

The result of these studies can take 10 years or more, but this medication could be available many years before that.

[Cja1956]

That looks like a really interesting study but it seems like it’s be difficult to find people because their criteria is so strict.

[Manouche in reply to Cja1956]

Not that difficult. We’ll see the outcome of this trial in 9 months on the first 21 participants

Detailed Description:

This study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GB2064 a LOXL-2 inhibitor over 9 months. Subjects will receive doses of GB2064, given twice per day to participants with primary or secondary Myelofibrosis

Interventional (Clinical Trial)

Estimated Enrollment :

21 participants

clinicaltrials.gov/ct2/show...